Bacteriology of sUrGical Site INfection Following Surgery for Intestinal Failure (BUGS-IN-IF)
Prospective Bacteriology of sUrGical Site INfection Following Surgery for Intestinal Failure
This is a prospective observational study of patients undergoing planned surgery for intestinal failure. The aims of the study are:
- To prospectively characterise preoperative bacterial populations amongst patients undergoing surgery for intestinal failure
- To examine the relationship between preoperative bacteriology and surgical site infection (SSI) in this patient group
- To investigate the effect of surgery and surgical site infection on generic and wound specific quality of life measures
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Harry F Dean
- Phone Number: +44 7375889207
- Email: harry.dean1@nhs.net
Study Locations
-
-
London
-
Harrow, London, United Kingdom, HA1 3UJ
- St Marks Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adults aged >18 year
- Diagnosis of intestinal failure or enterocutaneous fistula
- Undergoing elective surgery within St Mark's hospital IF unit
Exclusion Criteria:
- Unable or unwilling to provide informed consent
- Pregnant
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients with intestinal failure or an enterocutaneous fistula undergoing elective surgery.
Adult patients with a diagnosis of intestinal failure (IF) or an enterocutaneous fistula (ECF) undergoing planned surgery in our unit.
|
Patients will have swabs taken from the nose, mouth, umbilical skin, groin skin, fistula(e), stoma(s) and vascular access device prior to surgery.
Patients will be followed for 90 days postoperatively for surgical site infection (SSI) as defined by the centre for disease control (CDC) criteria 2021.
Patients who develop an SSI will have both preoperative and postoperative samples sent for genome sequencing.
Patients will complete baseline preoperative questionnaires which will be repeated at 30 days and 90 days.
These will evaluate generic and wound specific quality of life as well as decision conflict/decision regret.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical Surgical Site Infection (SSI)
Time Frame: 0-90 days
|
Classified as either superficial, deep or organ space as defined by the centre for disease control (CDC) classification 2021
|
0-90 days
|
|
Microbiological
Time Frame: 0-90 days
|
Preoperative colonisation species, Organisms cultured from SSI, Correlation to preoperative samples
|
0-90 days
|
|
Change in Generic Quality of Life Score
Time Frame: Baseline - 90 days
|
Generic health scores quantified by the validated EuroQoL 5 dimension, 5 level questionnaire (EQ5D-5L) at baseline, 30 and 90 days.
(Minimum score 5, Maximum score 25)
|
Baseline - 90 days
|
|
Change in Wound Specific Quality of Life Score
Time Frame: Baseline - 90 days
|
Quantified by the Wound-QoL questionnaire, a validated 17 item scale at baseline, 30 and 90 days (Minimum score 0, Maximum score 68)
|
Baseline - 90 days
|
|
Decision conflict
Time Frame: Day 0
|
Preoperative decision conflict scores quantified by decision conflict scale (DCS), a validated 16 point scale (Minimum score 0, Maximum score 64)
|
Day 0
|
|
Change in Decision Regret
Time Frame: 30 and 90 days
|
Postoperative decision regret scores quantified by the decision regret scale (DRS) a validated 5 item questionnaire, at 30 and 90 days.
(Minimum score 5, Maximum score 25)
|
30 and 90 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Length of stay
Time Frame: from day of surgery (day 0)
|
Duration of index hospital admission, measured in days
|
from day of surgery (day 0)
|
|
Complications
Time Frame: 90 days
|
Classified using the Clavien-Dindo classification(I-V)
|
90 days
|
|
Abdominal wound healing
Time Frame: 90 days
|
Classified as either 'completely healed' OR 'incompletely healed'
|
90 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Carolynne F Vaizey, St Marks Hospital & Academic Institute
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Postoperative Complications
- Wounds and Injuries
- Disease Attributes
- Gastrointestinal Diseases
- Pathological Conditions, Anatomical
- Digestive System Fistula
- Infections
- Communicable Diseases
- Fistula
- Intestinal Diseases
- Surgical Wound
- Surgical Wound Infection
- Wound Infection
- Intestinal Fistula
Other Study ID Numbers
Other Study ID Numbers
- RD21/049
- 301274 (Other Identifier: IRAS)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.